{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:26:49Z","timestamp":1794605209270,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review aims to provide a comprehensive overview of mavacamten in the management of obstructive hypertrophic cardiomyopathy (oHCM), from its molecular mechanism of action to clinical trial outcomes and real-world application. It explores the efficacy, safety, and practical considerations of mavacamten use, while highlighting evolving indications and future directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Randomized trials have shown that mavacamten significantly reduces left ventricular outflow tract gradients, improves symptoms and exercise capacity, and induces structural reverse remodeling with a favorable safety profile. Real-world data confirm these benefits in broader patient populations. Pharmacogenetic variability, titration protocols, and cost-effectiveness analyses have further refined its clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Mavacamten represents a paradigm shift in oHCM treatment by targeting disease at its sarcomeric origin. Its integration into routine care is expanding, supported by real-world evidence. Ongoing studies will clarify its role in non-obstructive HCM, heart failure with preserved ejection fraction, pediatric populations, and early-stage disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-025-02316-6","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:16:04Z","timestamp":1764591364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data"],"prefix":"10.1007","volume":"27","author":[{"given":"Giorgia","family":"Panichella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Ragagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Ilaria","family":"Fanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Zampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Del Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2316_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232\u20139.","journal-title":"Circulation"},{"key":"2316_CR2","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","volume":"44","author":"E Braunwald","year":"2023","unstructured":"Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J. 2023;44:4622\u201333.","journal-title":"Eur Heart J"},{"key":"2316_CR3","doi-asserted-by":"publisher","first-page":"e038758","DOI":"10.1161\/JAHA.124.038758","volume":"14","author":"BJ Davis","year":"2025","unstructured":"Davis BJ, Volk H, Nguyen O, et al. Safety and efficacy of Mavacamten and Aficamten in patients with hypertrophic cardiomyopathy. J Am Heart Association. 2025;14:e038758.","journal-title":"J Am Heart Association"},{"key":"2316_CR4","first-page":"735","volume":"11","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski JW, Guo R, Elliott PM, Ho CY. Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy. JACC: Heart Failure. 2023;11:735\u201348.","journal-title":"JACC: Heart Failure"},{"key":"2316_CR5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","volume":"141","author":"CN Toepfer","year":"2020","unstructured":"Toepfer CN, Garfinkel AC, Venturini G, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation. 2020;141:828\u201342.","journal-title":"Circulation"},{"key":"2316_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","volume":"82","author":"C Palandri","year":"2022","unstructured":"Palandri C, Santini L, Argir\u00f2 A, Margara F, Doste R, Bueno-Orovio A, et al. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82:889\u2013912.","journal-title":"Drugs"},{"key":"2316_CR7","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of Mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018;115:E8143-52.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2316_CR8","doi-asserted-by":"crossref","unstructured":"Cail RC, Baez-Cruz FA, Winkelmann DA, Goldman YE, Michael Ostap E. (2024) Dynamics of \u03b2-cardiac myosin between the super-relaxed and disordered-relaxed States. bioRxiv 2024.12.14.628474.","DOI":"10.1101\/2024.12.14.628474"},{"key":"2316_CR9","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.bpj.2011.02.061","volume":"100","author":"P Hooijman","year":"2011","unstructured":"Hooijman P, Stewart MA, Cooke R. A new state of cardiac myosin with very slow ATP turnover: a potential cardioprotective mechanism in the heart. Biophys J. 2011;100:1969\u201376.","journal-title":"Biophys J"},{"key":"2316_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.121.056324","volume":"144","author":"MJ Daniels","year":"2021","unstructured":"Daniels MJ, Fusi L, Semsarian C, Naidu SS. Getting inside the engine - myosin modulation in hypertrophic cardiomyopathy and systolic heart failure. Circulation. 2021;144:759\u201362.","journal-title":"Circulation"},{"key":"2316_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180064","volume":"12","author":"JW McNamara","year":"2017","unstructured":"McNamara JW, Li A, Lal S, Bos JM, Harris SP, van der Velden J, et al. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. PLoS ONE. 2017;12:e0180064.","journal-title":"PLoS ONE"},{"key":"2316_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat1199","volume":"11","author":"CN Toepfer","year":"2019","unstructured":"Toepfer CN, Wakimoto H, Garfinkel AC, et al. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci Transl Med. 2019;11:eaat1199.","journal-title":"Sci Transl Med"},{"key":"2316_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.24634","volume":"6","author":"L Alamo","year":"2017","unstructured":"Alamo L, Ware JS, Pinto A, Gillilan RE, Seidman JG, Seidman CE, et al. Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. Elife. 2017;6:e24634.","journal-title":"Elife"},{"key":"2316_CR14","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1016\/j.celrep.2016.11.040","volume":"17","author":"AS Adhikari","year":"2016","unstructured":"Adhikari AS, Kooiker KB, Sarkar SS, Liu C, Bernstein D, Spudich JA, et al. Early-onset hypertrophic cardiomyopathy mutations significantly increase the velocity, force, and actin-activated ATPase activity of human \u03b2-cardiac myosin. Cell Rep. 2016;17:2857\u201364.","journal-title":"Cell Rep"},{"key":"2316_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617\u201321.","journal-title":"Science"},{"key":"2316_CR16","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292:16571\u20137.","journal-title":"J Biol Chem"},{"key":"2316_CR17","doi-asserted-by":"publisher","first-page":"10487","DOI":"10.1074\/jbc.RA118.002081","volume":"293","author":"P Robinson","year":"2018","unstructured":"Robinson P, Liu X, Sparrow A, Patel S, Zhang Y-H, Casadei B, et al. Hypertrophic cardiomyopathy mutations increase myofilament Ca2\u2009+\u2009buffering, alter intracellular Ca2\u2009+\u2009handling, and stimulate Ca2+-dependent signaling. J Biol Chem. 2018;293:10487\u201399.","journal-title":"J Biol Chem"},{"key":"2316_CR18","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1111\/bph.15271","volume":"177","author":"PO Awinda","year":"2020","unstructured":"Awinda PO, Bishaw Y, Watanabe M, Guglin MA, Campbell KS, Tanner BCW. Effects of Mavacamten on Ca2\u2009+\u2009sensitivity of contraction as sarcomere length varied in human myocardium. Br J Pharmacol. 2020;177:5609\u201321.","journal-title":"Br J Pharmacol"},{"key":"2316_CR19","doi-asserted-by":"publisher","first-page":"H1112","DOI":"10.1152\/ajpheart.00325.2020","volume":"320","author":"LR Sewanan","year":"2021","unstructured":"Sewanan LR, Shen S, Campbell SG. Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue. Am J Physiol Heart Circ Physiol. 2021;320:H1112-23.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2316_CR20","doi-asserted-by":"publisher","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","volume":"320","author":"PO Awinda","year":"2021","unstructured":"Awinda PO, Watanabe M, Bishaw Y, Huckabee AM, Agonias KB, Kazmierczak K, et al. Mavacamten decreases maximal force and Ca2\u2009+\u2009sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2021;320:H881-90.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2316_CR21","doi-asserted-by":"publisher","first-page":"H715","DOI":"10.1152\/ajpheart.00023.2020","volume":"318","author":"AJ Sparrow","year":"2020","unstructured":"Sparrow AJ, Watkins H, Daniels MJ, Redwood C, Robinson P. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2\u2009+\u2009flux caused by thin filament hypertrophic cardiomyopathy mutations. Am J Physiol Heart Circ Physiol. 2020;318:H715-22.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2316_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009627","volume":"7","author":"R Mamidi","year":"2018","unstructured":"Mamidi R, Li J, Doh CY, Verma S, Stelzer JE. Impact of the myosin modulator Mavacamten on force generation and cross-bridge behavior in a murine model of hypercontractility. J Am Heart Assoc. 2018;7:e009627.","journal-title":"J Am Heart Assoc"},{"key":"2316_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170:741\u20138.","journal-title":"Ann Intern Med"},{"key":"2316_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030607","volume":"13","author":"A Masri","year":"2024","unstructured":"Masri A, Lester SJ, Stendahl JC, Hegde SM, Sehnert AJ, Balaratnam G, et al. Long-term safety and efficacy of Mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE study. J Am Heart Assoc. 2024;13:e030607.","journal-title":"J Am Heart Assoc"},{"key":"2316_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369.","journal-title":"Lancet"},{"key":"2316_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian Z, Li L, Li X, et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 2023;8:957\u201365.","journal-title":"JAMA Cardiol"},{"key":"2316_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"2316_CR28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","volume":"151","author":"MY Desai","year":"2025","unstructured":"Desai MY, Wolski K, Owens A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM. Circulation. 2025;151:1378\u201390.","journal-title":"Circulation"},{"key":"2316_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader F, Or\u0119ziak A, Choudhury L, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE Study, EXPLORER-LTE cohort. JACC Heart Fail. 2024;12:164\u201377.","journal-title":"JACC Heart Fail"},{"key":"2316_CR30","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75:2649\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"2316_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","volume":"13","author":"MY Desai","year":"2025","unstructured":"Desai MY, Nissen SE, Abraham T, et al. Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy: Design, Rationale, and baseline characteristics of ODYSSEY-HCM. JACC Heart Fail. 2025;13:358\u201370.","journal-title":"JACC Heart Fail"},{"key":"2316_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.cardfail.2024.10.449","volume":"31","author":"A Wang","year":"2025","unstructured":"Wang A, Lakdawala NK, Abraham TP, Nilles EK, Wojdyla DM, Owens AT, et al. Association between age or duration of diagnosis in obstructive hypertrophic cardiomyopathy and response to Mavacamten treatment: exploratory analysis of the EXPLORER-HCM trial. J Card Fail. 2025;31:901\u201311.","journal-title":"J Card Fail"},{"key":"2316_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jchf.2023.07.030","volume":"12","author":"A Wang","year":"2024","unstructured":"Wang A, Spertus JA, Wojdyla DM, Abraham TP, Nilles EK, Owens AT, et al. Mavacamten for obstructive hypertrophic cardiomyopathy with or without hypertension: post-hoc analysis of the EXPLORER-HCM trial. JACC Heart Fail. 2024;12:567\u201379.","journal-title":"JACC Heart Fail"},{"key":"2316_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1161\/CIRCULATIONAHA.123.065600","volume":"149","author":"S Cresci","year":"2024","unstructured":"Cresci S, Bach RG, Saberi S, et al. Effect of Mavacamten in women compared with men with obstructive hypertrophic cardiomyopathy: insights from EXPLORER-HCM. Circulation. 2024;149:498\u2013509.","journal-title":"Circulation"},{"key":"2316_CR35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jchf.2025.02.005","volume":"13","author":"MY Desai","year":"2025","unstructured":"Desai MY, Saberi S, Geske JB, et al. Long-Term response of obstructive hypertrophic cardiomyopathy patients to Mavacamten based on sex: insights from the VALOR-HCM trial. JACC Heart Fail. 2025;13:1037\u201340.","journal-title":"JACC Heart Fail"},{"key":"2316_CR36","doi-asserted-by":"crossref","unstructured":"Ochala J, Feng M, Wang Q et al. (2025) Heterogeneous dysregulation of myosin Super-Relaxation and energetics in hypertrophic cardiomyopathy. Circ Heart Fail e012614.","DOI":"10.1161\/CIRCHEARTFAILURE.124.012614"},{"key":"2316_CR37","doi-asserted-by":"crossref","unstructured":"Desai MY, Owens A, Saberi S et al. (2025) Long-Term effects of Mavacamten on patients based on hypertrophic cardiomyopathy pathogenic genetic variant status: insights from VALOR-HCM trial. Circ Genom Precis Med e005100.","DOI":"10.1161\/CIRCGEN.125.005100"},{"issue":"5","key":"2316_CR38","doi-asserted-by":"publisher","first-page":"S596","DOI":"10.1016\/j.hrthm.2024.03.1495","volume":"21","author":"M Austin","year":"2024","unstructured":"Austin M, Marzolf A, Hwang I, Puhl J, de Feria A, Reza N, et al. PO-05-054 dynamic impact of Mavacamten on ECG patterns of left ventricular hypertrophy with left ventricular strain. Heart Rhythm. 2024;21:S596.","journal-title":"Heart Rhythm"},{"key":"2316_CR39","volume":"2","author":"KC Siontis","year":"2023","unstructured":"Siontis KC, Abreau S, Attia ZI, et al. Patient-Level artificial Intelligence\u2013Enhanced electrocardiography in hypertrophic cardiomyopathy. JACC: Advances. 2023;2:100582.","journal-title":"JACC: Advances"},{"key":"2316_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011188","volume":"17","author":"A Del Franco","year":"2024","unstructured":"Del Franco A, Palinkas ED, Bellagamba CCA, Biagioni G, Zampieri M, Marchi A, et al. Long-term effects of Mavacamten on electromechanical dispersion and deformation in obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 2024;17:e011188.","journal-title":"Circ Heart Fail"},{"key":"2316_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13041005","volume":"13","author":"A Badr","year":"2025","unstructured":"Badr A, Roehl K, Suppah M, Abo Abdullah H, Arsanjani R, Siontis KC, et al. Temporal patterns of Holter-detected arrhythmias in hypertrophic cardiomyopathy patients treated with Mavacamten. Biomedicines. 2025;13:1005.","journal-title":"Biomedicines"},{"key":"2316_CR42","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","volume":"21","author":"M Castrichini","year":"2024","unstructured":"Castrichini M, Alsidawi S, Geske JB, Newman DB, Arruda-Olson AM, Bos JM, et al. Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten. Heart Rhythm. 2024;21:2065\u20137.","journal-title":"Heart Rhythm"},{"key":"2316_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1253\/circj.CJ-24-0501","volume":"89","author":"H Kitaoka","year":"2024","unstructured":"Kitaoka H, Ieda M, Ebato M, et al. Phase 3 open-label study evaluating the efficacy and safety of Mavacamten in Japanese adults with obstructive hypertrophic cardiomyopathy - the HORIZON-HCM study. Circ J. 2024;89:130\u20138.","journal-title":"Circ J"},{"key":"2316_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","volume":"86","author":"MY Desai","year":"2024","unstructured":"Desai MY, Hajj-Ali A, Rutkowski K, Ospina S, Gaballa A, Emery M, et al. Real-world experience with Mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center. Prog Cardiovasc Dis. 2024;86:62\u20138.","journal-title":"Prog Cardiovasc Dis"},{"key":"2316_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacep.2024.10.014","volume":"11","author":"TA Boyle","year":"2025","unstructured":"Boyle TA, Reza N, Hyman M, et al. Atrial fibrillation in patients receiving Mavacamten for obstructive hypertrophic cardiomyopathy: Real-World Incidence, Management, and outcomes. JACC Clin Electrophysiol. 2025;11:411\u20133.","journal-title":"JACC Clin Electrophysiol"},{"key":"2316_CR46","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0735-1097(25)02015-7","volume":"85","author":"M Yildiz","year":"2025","unstructured":"Yildiz M, Muuse J, Schmidt C, Palmer C, Pelchovitz DJ, Schloss EJ, et al. Mavacamten and atrial fibrillation risk: insights from a single-center prospective study. J Am Coll Cardiol. 2025;85:1531\u20131531.","journal-title":"J Am Coll Cardiol"},{"key":"2316_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi S, Cardim N, Yamani M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation. 2021;143:606\u20138.","journal-title":"Circulation"},{"key":"2316_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.017185","volume":"17","author":"MY Desai","year":"2024","unstructured":"Desai MY, Okushi Y, Gaballa A, et al. Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from the VALOR-HCM trial. Circ Cardiovasc Imaging. 2024;17:e017185.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2316_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","volume":"18","author":"MY Desai","year":"2025","unstructured":"Desai MY, Okushi Y, Wolski K, et al. Mavacamten-Associated Temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial. JACC Cardiovasc Imaging. 2025;18:251\u201362.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2316_CR50","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","volume":"78","author":"SM Hegde","year":"2021","unstructured":"Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78:2518\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"2316_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40119-025-00409-5","volume":"14","author":"Z Tian","year":"2025","unstructured":"Tian Z, Li X, Li L, et al. Effect of Mavacamten on echocardiographic features in Chinese patients with obstructive hypertrophic cardiomyopathy: results from the EXPLORER-CN study. Cardiol Ther. 2025;14:267\u201382.","journal-title":"Cardiol Ther"},{"key":"2316_CR52","doi-asserted-by":"crossref","unstructured":"Cresci S, Bach RG, Owens AT, Lakdawala NK, Saberi S, Hegde SM, Nilles EK, Wojdyla DM, Sehnert AJ, Wang A. (2025) Response to Mavacamten in patients with high baseline left ventricular filling pressures in the EXPLORER-HCM trial. Circ Cardiovasc Imaging e017824.","DOI":"10.1161\/CIRCIMAGING.124.017824"},{"key":"2316_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.014986","volume":"15","author":"PC Cremer","year":"2022","unstructured":"Cremer PC, Geske JB, Owens A, et al. Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study. Circ Cardiovasc Imaging. 2022;15:e014986.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2316_CR54","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","volume":"397","author":"JA Spertus","year":"2021","unstructured":"Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2467\u201375.","journal-title":"Lancet"},{"key":"2316_CR55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","volume":"8","author":"MT Wheeler","year":"2023","unstructured":"Wheeler MT, Olivotto I, Elliott PM, et al. Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial. JAMA Cardiol. 2023;8:240\u20137.","journal-title":"JAMA Cardiol"},{"key":"2316_CR56","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European society of cardiology (ESC). Eur Heart J. 2023;44:3503\u2013626.","journal-title":"Eur Heart J"},{"key":"2316_CR57","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: A report of the American heart Association\/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2024;149:e1239\u2013311.","journal-title":"Circulation"},{"key":"2316_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10741-024-10464-0","volume":"30","author":"A Aimo","year":"2025","unstructured":"Aimo A, Todiere G, Barison A, Tomasoni D, Panichella G, Masri A, et al. Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines. Heart Fail Rev. 2025;30:315\u201325.","journal-title":"Heart Fail Rev"},{"key":"2316_CR59","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2506225","volume":"25","author":"A Amr","year":"2024","unstructured":"Amr A, Kayvanpour E, Reich C, Koelemen J, Asokan S, Frey N, et al. Assessing the applicability of cardiac myosin inhibitors for hypertrophic cardiomyopathy management in a large single center cohort. Rev Cardiovasc Med. 2024;25:225.","journal-title":"Rev Cardiovasc Med"},{"key":"2316_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ejhf.3120","volume":"26","author":"E Bertero","year":"2024","unstructured":"Bertero E, Chiti C, Schiavo MA, et al. Real-world candidacy to Mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population. Eur J Heart Fail. 2024;26:59\u201364.","journal-title":"Eur J Heart Fail"},{"key":"2316_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2459\/JCM.0000000000001746","volume":"26","author":"C de Gregorio","year":"2025","unstructured":"de Gregorio C, Bellocchi P, Napoli AR, et al. Myosin-ATPase inhibitor in real-world patients with obstructive HCM: a report by the cardiomyopathies and pericardial diseases WG of the Italian society of cardiology. J Cardiovasc Med (Hagerstown). 2025;26:381\u20135.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2316_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.acvd.2024.04.001","volume":"117","author":"A Parodi","year":"2024","unstructured":"Parodi A, Puscas T, R\u00e9ant P, et al. Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: real-life estimation from the French register of hypertrophic cardiomyopathy (REMY). Arch Cardiovasc Dis. 2024;117:427\u201332.","journal-title":"Arch Cardiovasc Dis"},{"key":"2316_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100710","volume":"2","author":"OM Abdelfattah","year":"2023","unstructured":"Abdelfattah OM, Lander B, Demarco K, Richards K, Dubose D, Martinez MW. Mavacamten short-term hemodynamic, functional, and electrocardiographic outcomes: initial real-world post-trial experience. JACC Adv. 2023;2:100710.","journal-title":"JACC Adv"},{"key":"2316_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02544-w","author":"F Becker","year":"2024","unstructured":"Becker F, Novotny J, Jansen N, Clau\u00df S, M\u00f6ller-Dyrna F, Specht B, Orban M, Massberg S, K\u00e4\u00e4b S, Reichart D. Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor Mavacamten in an outpatient clinic cohort during the 12-week Titration period. Clin Res Cardiol. 2024. https:\/\/doi.org\/10.1007\/s00392-024-02544-w.","journal-title":"Clin Res Cardiol"},{"key":"2316_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1429230","volume":"11","author":"DS Kim","year":"2024","unstructured":"Kim DS, Chu EL, Keamy-Minor EE, et al. One-year real-world experience with Mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy. Front Cardiovasc Med. 2024;11:1429230.","journal-title":"Front Cardiovasc Med"},{"key":"2316_CR66","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034069","volume":"13","author":"D Ramonfaur","year":"2024","unstructured":"Ramonfaur D, Gasperetti A, Blake VE, Rivers B, Kassamali AA, Kasper EK, et al. Eighteen-month real-world experience using Mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population. J Am Heart Assoc. 2024;13:e034069.","journal-title":"J Am Heart Assoc"},{"key":"2316_CR67","first-page":"1123","volume":"12","author":"N Reza","year":"2024","unstructured":"Reza N, Dubey A, Carattini T, Marzolf A, Hornsby N, de Feria A, et al. Real-world experience and 36-week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with Mavacamten. JACC: Heart Failure. 2024;12:1123\u20135.","journal-title":"JACC: Heart Failure"},{"key":"2316_CR68","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.amjcard.2025.01.032","volume":"242","author":"Z Abood","year":"2025","unstructured":"Abood Z, Jan MF, Ashraf M, et al. Real-world assessment of mavacamten\u2019s impact on left ventricular systolic and diastolic functions in obstructive hypertrophic cardiomyopathy: a 1-year single-center observational study. Am J Cardiol. 2025;242:68\u201374.","journal-title":"Am J Cardiol"},{"key":"2316_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2025-003218","volume":"12","author":"E Burford","year":"2025","unstructured":"Burford E, Kasolo Y, Draper J, Sheikh N, Carr-White G, de Marvao A, et al. Tale of three services: early UK experience with Mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. Open Heart. 2025;12:e003218.","journal-title":"Open Heart"},{"key":"2316_CR70","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2024.0443","author":"J Lim","year":"2025","unstructured":"Lim J, Cho JY, Kwak S, et al. Real-world experience of Mavacamten for patients with obstructive hypertrophic cardiomyopathy in South korea: a prospective multi-center observational study. Korean Circ J. 2025. https:\/\/doi.org\/10.4070\/kcj.2024.0443.","journal-title":"Korean Circ J"},{"key":"2316_CR71","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.jacadv.2024.101430","volume":"4","author":"MW Martinez","year":"2025","unstructured":"Martinez MW, Seto D, Cheung M, Coiro M, Patel N, Bastien A, Lockman J, Afsari S, Desai MY. Mavacamten: initial insights from the risk evaluation and mitigation strategy program. JACC Adv. 2025;4:101430.","journal-title":"JACC Adv"},{"key":"2316_CR72","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40256-024-00672-2","volume":"24","author":"Z Yukselen","year":"2024","unstructured":"Yukselen Z, Raju AKV, Kumar PA, Ujjawal A, Dasari M, Parajuli S, et al. A real\u2013world pharmacovigilance study of FDA adverse event reporting system (FAERS) for Mavacamten. Am J Cardiovasc Drugs. 2024;24:791\u20139.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2316_CR73","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.123.066916","volume":"149","author":"KA McGurk","year":"2024","unstructured":"McGurk KA, Bilgehan N, Ware JS. Pharmacogenetic influences over Mavacamten pharmacokinetics: considerations for the treatment of individuals with hypertrophic cardiomyopathy. Circulation. 2024;149:1786\u20138.","journal-title":"Circulation"},{"key":"2316_CR74","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/cpdd.1332","volume":"12","author":"V Perera","year":"2023","unstructured":"Perera V, Gretler DD, Seroogy JD, Chiang M, Palmisano M, Florea V. Effects of omeprazole and verapamil on the pharmacokinetics, safety, and tolerability of mavacamten: two drug-drug interaction studies in healthy participants. Clin Pharmacol Drug Dev. 2023;12:1241\u201351.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2316_CR75","doi-asserted-by":"publisher","first-page":"695","DOI":"10.4155\/bio-2023-0030","volume":"15","author":"SN Rao Gajula","year":"2023","unstructured":"Rao Gajula SN, Talari S, Nathani TN, Munjal V, Rahman Z, Dandekar MP, et al. Effect of chronopharmacology and food on in vivo pharmacokinetic profile of Mavacamten. Bioanalysis. 2023;15:695\u2013706.","journal-title":"Bioanalysis"},{"key":"2316_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-025-01808-0","author":"F-E Cott\u00e9","year":"2025","unstructured":"Cott\u00e9 F-E, Hurst M, Akarkoub S, Ho M, Vernon J, Chambry L, Leproust S. Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective. Eur J Health Econ. 2025. https:\/\/doi.org\/10.1007\/s10198-025-01808-0.","journal-title":"Eur J Health Econ"},{"key":"2316_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clinthera.2021.11.006","volume":"44","author":"N Desai","year":"2022","unstructured":"Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, Garrison LP. Projecting the Long-term clinical value of Mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the united states: an assessment of net health benefit. Clin Ther. 2022;44:52\u2013e662.","journal-title":"Clin Ther"},{"key":"2316_CR78","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.2737","volume":"25","author":"MT Wheeler","year":"2023","unstructured":"Wheeler MT, Jacoby D, Elliott PM, et al. Effect of beta-blocker therapy on the response to Mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Eur J Heart Fail. 2023;25:260\u201370.","journal-title":"Eur J Heart Fail"},{"key":"2316_CR79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ejhf.2768","volume":"25","author":"F Dominguez","year":"2023","unstructured":"Dominguez F, Cabrera E. Mavacamten in obstructive hypertrophic cardiomyopathy \u2013 are beta-blockers blocking part of its shine? Eur J Heart Fail. 2023;25:271\u20133.","journal-title":"Eur J Heart Fail"},{"key":"2316_CR80","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2316_CR81","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/phar.2874","volume":"43","author":"A Willeford","year":"2023","unstructured":"Willeford A, Silva Enciso J. Transitioning disopyramide to Mavacamten in obstructive hypertrophic cardiomyopathy: a case series and clinical guide. Pharmacotherapy. 2023;43:1397\u2013404.","journal-title":"Pharmacotherapy"},{"key":"2316_CR82","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jacc.2024.09.003","volume":"84","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, et al. Impact of Aficamten on disease and symptom burden in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM. J Am Coll Cardiol. 2024;84:1821\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"2316_CR83","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jchf.2024.11.011","volume":"13","author":"P Garcia-Pavia","year":"2025","unstructured":"Garcia-Pavia P, Bilen O, Burroughs M, et al. Aficamten vs Metoprolol for obstructive hypertrophic cardiomyopathy: MAPLE-HCM Rationale, study Design, and baseline characteristics. JACC Heart Fail. 2025;13:346\u201357.","journal-title":"JACC Heart Fail"},{"key":"2316_CR84","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamacardio.2024.3810","volume":"10","author":"SJ Shah","year":"2025","unstructured":"Shah SJ, Rigolli M, Javidialsaadi A, et al. Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. JAMA Cardiol. 2025;10:170\u20135.","journal-title":"JAMA Cardiol"},{"key":"2316_CR85","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011833","volume":"17","author":"J Almeida-Coelho","year":"2024","unstructured":"Almeida-Coelho J, Leite-Moreira AM, Sequeira V, Hamdani N, Louren\u00e7o AP, Falc\u00e3o-Pires I, et al. Myosin-inhibitor mavacamten acutely enhances cardiomyocyte diastolic compliance in heart failure with preserved ejection fraction. Circ Heart Fail. 2024;17:e011833.","journal-title":"Circ Heart Fail"},{"key":"2316_CR86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505927","author":"MY Desai","year":"2025","unstructured":"Desai MY, Owens AT, Abraham T, et al. Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2505927.","journal-title":"N Engl J Med"},{"issue":"1","key":"2316_CR87","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cardfail.2024.10.419","volume":"31","author":"C Dufton","year":"2025","unstructured":"Dufton C, Evanchik M, Daniel DD, Silverman JA, Marilyn MM, Madden M, et al. EDG-7500, a first-in-class cardiac sarcomere modulator, demonstrates favorable tolerability, safety, and pharmacokinetics in healthy adults. J Card Fail. 2025;31:345.","journal-title":"J Card Fail"},{"key":"2316_CR88","volume":"3","author":"D Saleh","year":"2025","unstructured":"Saleh D, Kim EY, Hussain K, et al. Anterior mitral valve leaflet length and response to Mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2025;3:qyaf081.","journal-title":"Eur Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02316-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:04:54Z","timestamp":1772096694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02316-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2316"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02316-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"169"}}